Aktuálne odporúčania pre prevenciu a liečbu fibrilácie predsiení a jej tromboembolických komplikácií.

According to the recent knowledge and new methods regarding management of atrial fibrillation, the European Society of Cardiology (ESC) has published (2010) its new Guidelines for the management of atrial fibrillation. The goal of this paper from the Angiologists' Section of the Slovak Medical Chamber is to present the updated guidelines to the readers in a more transparent and concise form. Much of the morbidity and mortality associated with atrial fibrillation is due to organovascular arterial thromboembolic complications, mainly involving the cerebrovascular arterial system and resulting in ischemic stroke. The limitation of current anticoagulation with vitamin K antagonists suggests the need for antithrombotic strategies or new antithrombotic drugs with more favourable safety profiles that do not require coagulation monitoring or dose adjustment. Dabigatran confirms better effect on stroke incidence and systemic arterial thromboembolization and lower risk of major bleeding in comparison with warfarin. Dronedarone is the first antiarrhythmic drug, which has reduced cardiovascular hospitalisation and mortality. [ABSTRACT FROM AUTHOR]